3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
5
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
304
Carcinoma, Non-Small-Cell Lung
182
Ovarian Neoplasms
154
Lung Neoplasms
92
Esophageal Neoplasms
75
Triple Negative Breast Neoplasms
71
Stomach Neoplasms
71
Fallopian Tube Neoplasms
68
Squamous Cell Carcinoma of Head and Neck
51
Esophageal Squamous Cell Carcinoma
50
Neoplasm Metastasis
48
Neoplasms
45
Endometrial Neoplasms
42
Head and Neck Neoplasms
41
Carcinoma, Ovarian Epithelial
41
Uterine Cervical Neoplasms
37
Recurrence
26
Carcinoma, Squamous Cell
23
Adenocarcinoma Of Esophagus
22
Urinary Bladder Neoplasms
19
Melanoma
19
Inflammatory Breast Neoplasms
19
Prostatic Neoplasms
18
Adenocarcinoma of Lung
17
Carcinoma
15
Breast Neoplasms, Male
15
Unspecified Adult Solid Tumor, Protocol Specific
14
Testicular Neoplasms
13
Small Cell Lung Carcinoma
12
Peritoneal Neoplasms
12
Interventions
Capecitabine
6
Irinotecan
5
Fluorouracil
5
Cisplatin
5
Oxaliplatin
4
Leucovorin
4
Gemcitabine
4
apatinib
3
Sorafenib
3
Bevacizumab
3
tislelizumab
2
pembrolizumab
2
Sunitinib
2
Radiotherapy
2
Paclitaxel
2
Immune Checkpoint Inhibitors
2
Cyclophosphamide
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
regorafenib
1
pyrotinib
1
pemigatinib
1
lutetium Lu 177 dotatate
1
huachansu
1
halofantrine
1
guadecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Digestive System Neoplasms
×
Paclitaxel
×
Clear all
NCT05262335
2023-11-28
ALTER-G-001
Ruijin Hospital
Phase 2
Unknown
116 enrolled
NCT05281003
2023-07-13
HYPERION
Fudan University
Phase 2
Recruiting
128 enrolled